Testing a new memory and thinking test for mild cognitive impairment and dementia
Checks how well the ASCA test detects mild cognitive impairment and dementia in older adults.
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Validating the Ain Shams Cognitive Assessment Tool
- Status
- Not yet recruiting
- People taking part
- 100 people, planned
- Started
- 1 Feb 2025
- Planned end
- 1 Jun 2025
- Type of study
- Observational, 3 groups
- Treatments tested
- Ain Shams University Cognitive Assessment (ASCA) tool
- Record updated
- 23 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 60 and above who are native Arabic speakers. It includes people with dementia, people with mild cognitive impairment (memory and thinking problems), and healthy people. It tests a memory and thinking test called ASCA.
- Age
- 60 years and above
- Sex
- All
- Disease stage
- Dementia or mild cognitive impairment diagnosed by DSM-5 criteria, or healthy controls. Severe dementia is not allowed.
Main reasons for not taking part
- Severe dementia
- Delirium (sudden confusion)
- Major mental disorders
- Aphasia (trouble with speech or language)
- Severe sight or hearing problems that get in the way of the test
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- -
Who cannot take part
- severe dementia, delirium, major mental disorders, aphasia, and those with severe visual or hearing impairment that interfere with the assessment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The diagnosis of cognitive impairment, including dementia and mild cognitive impairment (MCI), is crucial for timely intervention and management. Various screening tools are available for assessing cognitive function, among which the Mini-Mental State Examination (MMSE), the Addenbrooke's Cognitive Examination (ACE), and the Montreal Cognitive Assessment (MoCA) are widely used. However, the recently developed Ain Shams University Cognitive Assessment (ASCA) has shown promise in detecting early cognitive decline. This study aims to assess the performance of ASCA in diagnosing cognitive impairment against DSM5 criteria.
The 3 groups in the trial
- Dementia
participants \>60 years with Dementia diagnosed by DSM-5 criteria
Treatment: Ain Shams University Cognitive Assessment (ASCA) tool
- Mild cognitive impairment
participants \>60 years with Mild cognitive impairment (MCI) diagnosed by DSM-5 criteria
Treatment: Ain Shams University Cognitive Assessment (ASCA) tool
- control
euthymic healthy community dwelling adult participants of various socioeconomic and educational status.
Treatment: Ain Shams University Cognitive Assessment (ASCA) tool
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Validating the Ain Shams Cognitive Assessment (ASCA) for Diagnosing Mild Cognitive Impairment and Dementia
- Plain-language title
- Testing a new memory and thinking test for mild cognitive impairment and dementiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 23 January 2025